Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74

Summary by The Journal
The HARMONi-A study is the first Phase III trial of an immunotherapy for EGFR-TKI-resistant, EGFR-mutated non-squamous NSCLC to show statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS)With a median follow-up of 32.5 months,…

14 Articles

LoudounTimes.comLoudounTimes.com
+12 Reposted by 12 other sources
Center

Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74

The HARMONi-A study is the first Phase III trial of an immunotherapy for EGFR-TKI-resistant, EGFR-mutated non-squamous NSCLC to show statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS)With a median follow-up of 32.5 months,…

Read Full Article
oncnursingnews.comoncnursingnews.com

Durvalumab/FLOT Boosts OS in Resectable Gastric Cancer

Durvalumab plus FLOT chemotherapy improved overall survival in resectable gastric or gastroesophageal junction cancer, per phase 3 MATTERHORN data.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 83% of the sources are Center
83% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

oncnursingnews.com broke the news in on Friday, November 7, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Cancer icon

Cancer

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal